Primrose Bio

Join the Primrose Bio team! We're hiring a Senior Research Associate in our Molecular Biology group. If you're passionate about developing new genetic technologies and enjoy working in a collaborative environment on cutting-edge projects, we want to hear from you. Contribute to our innovative R&D programs and help create the next generation of superior enzymes and organisms.

We are excited to see Primrose Bio's continued progress. This investment by 1315 Capital further validates the strength of Primrose’s technology solutions which we expect to generate significant value for Primrose shareholders, including Ligand. As we announced last week, Merck’s CAPVAXIVE™ utilizes Primrose’s Pfenex Expression Technology® platform. Ligand is entitled to royalties on CAPVAXIVE as well as five additional commercial products developed with the Pfenex technology. We will also benefit from potential future revenues through additional partnerships with Primrose.

Now six products approved using the Pfenex Expression Technology! Merck's 21-valent CAPVAXIVE™ was approved by the US FDA yesterday and uses P. fluorescens-produced CRM197 as its carrier protein! Read more: https://lnkd.in/gH8tFA4p #crm197 #vaccines #pfenexexpressiontechnology

Primrose Bio announces a significant equity investment from 1315 Capital. “...With this investment, we are well-positioned to advance our therapeutic protein and nucleic acid manufacturing solutions with our existing large-pharma collaborators and future partners.” - Helge Zieler, CEO of Primrose. Read the full press release: https://lnkd.in/g6bkkNmp #PrimroseBio #1315Capital

With over 180 leads and more than 1,000 protein/peptide candidates, Pfenex Expression Technology® has demonstrated its versatility through the production and commercialization of a broad range of natural and engineered proteins across a multitude of classes. With over 20 years of success, our expression technology drives improvements from discovery to approval. Work with us: https://bit.ly/3VCt0kC #proteinexpression #primrosebio

Tomorrow, Daniel Olson, PhD, will present a poster on Primrose Bio's innovative approach to oligonucleotide manufacturing. This novel method promises to reduce production costs and eliminate hazardous solvents, offering a safer and more cost-effective solution for producing critical therapeutic components. Catch Dan at the Advances in Genomic Technology Development (AGTD) 2024 Annual Meeting, held at Jackson Laboratories for Genomic Medicine in Farmington, CT. The event runs through Thursday, June 13th. #EOS #DNA #Oligonucleotides #syntheticbiology

Our industry-proven Pfenex Expression Technology® platform starts with an automated, high-throughput, rapid candidate selection process that combines over 30 years of know-how in expressing challenging molecules. Unlike CHO and E. coli which have their roots as research tools, the Pfenex platform is based on Pseudomonas fluorescens and is specifically designed as an expression platform for producing large quantities of high quality, complex proteins at low cost. Work with us: https://bit.ly/3VkLlB6 #proteinexpression #primrosebio #pfenex

Michael Bacica, Principal Scientist of Primrose Bio, presented a poster today at American Society For Mass Spectrometry (ASMS)'s 72nd ASMS Conference on Mass Spectrometry and Allied Topics. Message Michael via the ASMS app to connect with him through June 6th at the Anaheim Convention Center. Learn how our Pfenex Expression Technology system, combined with HDX analysis, was used to determine a SARS-CoV-2 RBD binding epitope of a novel disulfide-rich bovine antibody fragment. #ASMS #proteinexpression

We are here at BIO's International Convention through June 6 in San Diego. Meet with Primrose Bio to learn more on our scalable, efficient, and cost-effective manufacturing solutions essential for novel vaccines and therapies! Connect with Michele Rubino, Louis J. Cantolupo and Alec Tzianabos via the BIO One-on-One Partnering System. #BIO #Primrosebio #vaccines #therapeutics

There are only seven days left until Biotechnology Innovation Organization's International Convention, June 3-6, 2024 in San Diego. Our calendars are filling up – book a meeting with Michele Rubino, Louis J. Cantolupo and Alec Tzianabos via the BIO One-on-One Partnering System today! Connect with Michele on our enhanced RNA polymerases, Prima RNApols™, and our Enzymatic Oligonucleotide Synthesis solutions. Learn more from Lou on improved protein expression via our flagship Pfenex Expression Technology® platform, and on our PeliCRM197® carrier protein, the only CRM197 used in commercial products available for purchase. Meet with Alec to also discuss complex protein expression via the Pfenex platform, as well as your superior RNA polymerases needs. #BIO #biotech #partnerships #innovation